Neoplasms, Hormone-Dependent
"Neoplasms, Hormone-Dependent" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
| Descriptor ID |
D009376
|
| MeSH Number(s) |
C04.626
|
| Concept/Terms |
Neoplasms, Hormone-Dependent- Neoplasms, Hormone-Dependent
- Neoplasms, Hormone Dependent
- Hormone-Dependent Neoplasms
- Hormone Dependent Neoplasms
- Hormone-Dependent Neoplasm
- Neoplasm, Hormone-Dependent
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms, Hormone-Dependent".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Hormone-Dependent".
This graph shows the total number of publications written about "Neoplasms, Hormone-Dependent" by people in this website by year, and whether "Neoplasms, Hormone-Dependent" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1998 | 2 | 1 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 3 | 1 | 4 |
| 2004 | 5 | 1 | 6 |
| 2005 | 2 | 0 | 2 |
| 2006 | 4 | 1 | 5 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 1 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasms, Hormone-Dependent" by people in Profiles.
-
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
-
Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers. Biochem Pharmacol. 2017 09 15; 140:1-7.
-
The Role of Steroid Receptor Coactivators in Hormone Dependent Cancers and Their Potential as Therapeutic Targets. Horm Cancer. 2016 08; 7(4):229-35.
-
Cyclin D1 Promotes Androgen-Dependent DNA Damage Repair in Prostate Cancer Cells. Cancer Res. 2016 Jan 15; 76(2):329-38.
-
The mammary stem cell hierarchy: a looking glass into heterogeneous breast cancer landscapes. Endocr Relat Cancer. 2015 Dec; 22(6):T161-76.
-
Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer. J Clin Invest. 2014 Nov; 124(11):5013-26.
-
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
-
First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist. 2013; 18(5):501-10.
-
Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2012 Sep; 135(2):619-27.
-
The importance of nonpharmacogenetic factors in endocrine therapy. Pharmacogenomics. 2012 Apr; 13(6):721-8.